What is Numinus Wellness Inc.?
Numinus Wellness Inc. is a Canadian health care firm that develops and delivers safe, evidence-based psychedelic-assisted therapies for the treatment of mental illness, substance misuse, and trauma. The company’s mission is to enable healing and wellness in the communities it serves.
Psychedelic production, clinical research, and clinical care are all components of the Numinus Concept. Which is support by a research facility that is license by Health Canada. An experienced medical team and an expanding network of clinics.
The licence held by the company enables it to engage in a wide variety of research endeavours in addition to the import, export, and distribution of psychedelic chemicals such as DMT, ketamine, LSD, MDMA, mescaline, and psilocybin and psilocin.
The company conducts its business via the following divisions: Salvation Botanicals, Numinus Health, and Salvation Bioscience. Research on psychedelic substances is conduct by the Salvation Botanicals division. Which also works to build its intellectual property and provides analytical services to customers to generate income.
Its laboratory offers a variety of services in the field of psychedelics, including cultivation, analytical testing, product research and development, and supplementary services. The wellness centre that focus on treating mental health and substance misuse is run by the Numinus Health division. Which also provides professional therapists and medical experts that work there with supportive therapies and technologies. Payton Nyquvest and Stacey Wallin established the business in 2018, and it currently has its headquarters in Vancouver, in the country of Canada.
Numinus Wellness Inc. Stock Analysis:
Stock Target Advisor’s own stock analysis of Numinus Wellness Inc. is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Numinus Wellness Inc.’s stock price was CAD 0.43. Numinus Wellness Inc.’s stock price has changed by +32.81% over the past week, -11.46% over the past month and -52.78% over the last year.
What to like:
Superior risk-adjusted returns
This stock has performed well, on a risk-adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.
What to not like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquire in future.
High volatility
The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cash flow
The company had negative total cash flow in the most recent four quarters.
Latest News for Numius Wellness Inc.
Numinus’s first half of fiscal 2022 (H1FY22) sales doubled to C$1.6mln from C$1.5mln for all of FY21. This was supported by the first-quarter or Q1 (September 2021) acquisition of the Neurology Centre of Toronto. Numimus reported H1FY22 gross profit of C$0.3mln vs an H1FY21 gross loss of C$0.1mln.
The acquisition of Novamind, slated to be finalised in June 2022, will bring around C$8mln of annualised revenues at a 48 percent gross margin before growth. Novamind has eight US clinics in Utah and Arizona, plus two additional clinical research centers. We have updated our projections for this Q4FY22 acquisition.
Is Numinus Wellness a good buy?
Yes, Numinus Wellness is a good Penny stock (Penny stocks trade under a $1). In USA, the widespread licencing and distribution of drugs inspired by psychedelic experiences in order to treat mental health conditions such as attention deficit hyperactivity disorder (ADHD), addiction, and depression is being considered. It’s a tremendous movement right now. It’s like the second wave of the cannabis boom. In the end, it will result in a new category of drugs that can treat problems that, for many years, medical practitioners have considered to be incurable.
This megatrend is being led by Numinus Wellness, which is at the forefront of the industry. It is one of the few companies in the world that is actively pushing forward the front of psychedelic-inspired medicine, and in fact, one could argue that Numinus has emerged as a leader in this field. Numinus is one of the few companies in the world that is actively pushing forward the front of psychedelic-inspired medicine. However, the other people who consider “leaders” in this industry have a net worth of more than one billion dollars. Numinus has a market cap of less than $200 million and covered cash accounts for $65 million of that total market cap. The potential for LKYSF stock to appreciate significantly is quite clear.
